Eli Lilly and Company

A Study to Evaluate the Efficacy and Safety of Brenipatide in Adult Participants with Moderate-to-Severe COPD (RENEW-COPD)

Condition: Chronic Obstructive Pulmonary Disease

Testing For: Brenipatide

Trial ID: J2S-MC-GZMV

Age: 40-75 Years old

Phase: 2

Learn More

A Study Investigating Tersolisib (LY4064809) or Placebo Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with Breast Cancer with a PIK3CA Mutation

Condition: Advanced Breast Cancer

A Phase 3, Randomized, Double‑blind, Placebo‑controlled Study of LY4064809 (tersolisib) in Combination with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2‑ Advanced Breast Cancer with a PIK3CA Mutation (PIKALO‑2)

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Testing For: LY4064809 (Tersolisib)

Trial ID: J6M-MC-JSGD (PIKALO-2)

Age: 18+ years old

Phase: 2/3

Learn More

A Phase 3 Study of Olomorasib in Combination with Standard of Care in Participants with Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)

Condition: Non-Small Cell Lung Cancer

Testing For: olomorasib (LY3537982)

Trial ID: J3M-MC-JZQH

Age: 8+

Phase: 3

Learn More

A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/mirikizumab co-administration compared with mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease

Condition: Crohn’s Disease

Testing for: Mirikizumab (LY3074828) and LY4395089

Trial ID: J6Z-MC-CD01

Age: 18 to 80

Phase: 2

Learn More

A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer (SUNRAY-02)

Condition: Non-Small Cell Lung Cancer

Testing For: Olomorasib (LY3537982)

Trial ID: J3M-MC-JZQB

Age: Age: 18+

Learn More

A clinical trial for people who have irritable bowel syndrome with diarrhea (GZMS) (RENEW-IBS-D)

Condition: Irritable Bowel Syndrome-Diarrhea (IBS-D)

What the trial is testing: Brenipatide

Trial ID: J3S-MC-GZMS

Age: 18 to 75 years of age

Phase: 2

Learn More

A Clinical trial for people with irritable bowel syndrome with constipation (GZMT) (RENEW-IBS-C)

Condition: Irritable Bowel Syndrome-Constipation (IBS-C)

What the trial is testing: Brenipatide

Trial ID: J3S-MC-GZMT

Age: 18 to 75 years of age

Phase: 2

Learn More

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease (GARNET).

Condition: Crohn's Disease

A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease

Drugs: LY4268989 (MORF-057)

Trial ID: J6E-MC-KWAB

Age: 18 to 85

Phase: 2

Learn More

Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Condition: Non-Segmental Vitiligo

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAD

Age: 18 to ≤75 years of age

Phase: 2

Learn More

Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Severe Alopecia Areata

Condition: Severe Alopecia Areata

Testing For: XCL1/2 (LY4005130)

Trial ID: J5D-MC-FPAC

Age: 18 to ≤50 years of age

Phase: 2

Learn More

EMERALD-3: A Phase 2b/3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis

Testing for: LY4268989 (MORF-057)

Trial ID: J6E-MC-KWAM

Age: 18 - 80

Phase: 2 and 3

Learn More

A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)

Condition: Ovarian Cancer

Testing for: LY4170156, mirvetuximab soravtansine, topotecan, bevacizumab, paclitaxel, carboplatin, gemcitabine

Trial ID: J5E-MC-JZXB

Age: ≥18 years

Phase: 3

Learn More

FORAGER-2 Study: A clinical research study for people living with bladder cancer and a change in the FGFR3 gene

Condition: Bladder Cancer

A Study Investigating Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Trial ID: J4G-MC-JZVD

Age: ≥18 years

Phase: 3

Learn More

TOPAZ-UC: A Phase 2, Multicenter, Randomized, Double-Blind, Active- Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis

Condition: Ulcerative Colitis

Drugs: LY4268989 (MORF-057) and Mirikizumab (LY3074828)

Trial ID: J6E-MC-KWAN

Age: 18-80

Phase: 2

Learn More

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight (COMMIT-CD)

Condition: Crohn’s Disease, Obesity

Drugs: Mirikizumab, Tirzepatide

Trial ID: I6T-MC-AMCE

Age: 18-70 years

Phase: 3

Learn More

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) Conditions the trial is for: Ulcerative Colitis, Obesity

Condition: Ulcerative Colitis, Obesity

Trial ID: I6T-MC-AMCD

Age: 18-70 Years old

Phase: 3

Learn More

LEARN MORE ABOUT LILLY TRIALS

Where Culture Meets Care

LEARN MORE ABOUT LILLY TRIALS

Where Culture Meets Care

Download PDF